Efficacy of Chinese herbal injections combined with fluoropyrimidine and oxaliplatin-based chemotherapy for advanced colorectal cancer: A protocol for systematic review and meta-analysis of randomized controlled trials

• Published in: Medicine (Baltimore) Vol. 99; no. 52; p. e23550
• Main Authors: Wang, Shuo, Wang, Xueqian, Zhang, Ying, Zhou, Tong, Hu, Shuaihang, Tian, Peiyu, Li, Zheng, Li, Yuxiao, Gui, Yuerong, Dong, Jun, Hou, Wei
• Format: Journal Article
• Language: English
• Published: United States Lippincott Williams & Wilkins 24.12.2020
• Subjects: Antineoplastic Combined Chemotherapy Protocols - administration & dosage; Colorectal Neoplasms - drug therapy; Colorectal Neoplasms - pathology; Drug Combinations; Drugs, Chinese Herbal - administration & dosage; Humans; Injections; Meta-Analysis as Topic; Neoplasm Staging; Oxaliplatin - administration & dosage; Phytotherapy; Pyrimidines - administration & dosage; Randomized Controlled Trials as Topic; Research Design; Study Protocol Systematic Review; Systematic Reviews as Topic - methods; Treatment Outcome
• ISSN: 0025-7974; 1536-5964
• DOI: 10.1097/MD.0000000000023550

Fluoropyrimidine combined with oxaliplatin-based chemotherapy have become the first-line treatment for advanced colorectal cancer (CRC). Chinese herbal injections (CHIs), as an important part of TCM, have been widely applied as adjunctive treatments to chemotherapy in patients with advanced CRC. However, the efficacy of this combination therapy has not been evaluated comprehensively. We will conduct this systematic review and meta-analysis in accordance with the Preferred Reported Items for Systematic Review and Meta-analysis (PRISMA) guidelines. 7 databases will be searched for related randomized controlled trials (RCTs) from their inception to August 31, 2020: PubMed, Cochrane Library, EMBASE, China National Knowledge Infrastructure (CNKI), VIP Database for Chinese Technical Periodicals (VIP), SinoMED and Wanfang Database. Two researchers will perform study selection, data extraction, and assessment of risk of bias independently. The primary outcomes are the disease control rate (DCR) and the objective response rate (ORR), the secondary outcomes are progression-free survival (PFS), survival rate, quality of life (QoL) and adverse effects. Cochrane Review Manager (RevMan 5.3) software will be used to analyze the outcomes. This systematic review will evaluate the efficacy of CHIs and fluoropyrimidine and oxaliplatin-based chemotherapy for advanced CRC so as to provide valuable evidence to the application of CHIs in advanced CRC. INPLASY registration number: INPLASY2020100050.